Talphera, Inc. (NASDAQ:TLPH) Short Interest Update

Talphera, Inc. (NASDAQ:TLPH) was the recipient of a large decrease in short interest in the month of December. As of December 31st, there was short interest totalling 30,500 shares, a decrease of 49.0% from the December 15th total of 59,800 shares. Approximately 0.2% of the company’s stock are sold short. Based on an average trading volume of 111,000 shares, the days-to-cover ratio is presently 0.3 days.

Talphera Trading Up 6.8 %

NASDAQ:TLPH traded up $0.04 on Thursday, reaching $0.62. The stock had a trading volume of 60,294 shares, compared to its average volume of 96,759. Talphera has a 12-month low of $0.50 and a 12-month high of $1.61. The stock has a market cap of $10.56 million, a P/E ratio of -0.90 and a beta of 0.28. The company has a 50-day moving average of $0.67 and a 200 day moving average of $0.83.

Analysts Set New Price Targets

Separately, Maxim Group upgraded shares of Talphera to a “strong-buy” rating in a research note on Friday, November 8th.

Institutional Investors Weigh In On Talphera

A hedge fund recently bought a new stake in Talphera stock. Nantahala Capital Management LLC acquired a new stake in shares of Talphera, Inc. (NASDAQ:TLPH) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 1,992,519 shares of the company’s stock, valued at approximately $1,773,000. Nantahala Capital Management LLC owned approximately 11.73% of Talphera as of its most recent SEC filing. 37.67% of the stock is owned by institutional investors.

Talphera Company Profile

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.